These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 27688102)

  • 1. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Rischin D; Spigel DR; Adkins D; Wein R; Arnold S; Singhal N; Lee O; Murugappan S
    Head Neck; 2016 Apr; 38 Suppl 1():E1756-61. PubMed ID: 26681429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.
    Ferris RL; Geiger JL; Trivedi S; Schmitt NC; Heron DE; Johnson JT; Kim S; Duvvuri U; Clump DA; Bauman JE; Ohr JP; Gooding WE; Argiris A
    Ann Oncol; 2016 Dec; 27(12):2257-2262. PubMed ID: 27733374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
    Demirci NS; Aksoy S; Özdemir NY; Erdem GU; Ozcelik M; Tanrikulu E; Eren T; Bozkaya Y; Sahin S; Başol F; Aslan SA; Zengin N; Güllü İ
    Curr Med Res Opin; 2017 Mar; 33(3):401-407. PubMed ID: 27817239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
    Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
    Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
    Del Barco Morillo E; Mesía R; Adansa Klain JC; Vázquez Fernández S; Martínez-Galán J; Pastor Borgoñon M; González-Rivas C; Caballero Daroqui J; Berrocal A; Martínez-Trufero J; Vera R; Cruz-Hernández JJ;
    Oral Oncol; 2016 Nov; 62():54-59. PubMed ID: 27865372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
    Knoedler M; Gauler TC; Gruenwald V; Matzdorff A; Schroeder M; Dietz A; Jordan WO; Arnold D; Hennemann B; Hofele C; Weissinger F; Eberhardt W; Keilholz U
    Oncology; 2013; 84(5):284-9. PubMed ID: 23445718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
    Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
    Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study.
    Urba S; van Herpen CM; Sahoo TP; Shin DM; Licitra L; Mezei K; Reuter C; Hitt R; Russo F; Chang SC; Hossain AM; Frimodt-Moller B; Koustenis A; Hong RL
    Cancer; 2012 Oct; 118(19):4694-705. PubMed ID: 22434360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
    Chang PM; Tzeng CH; Chen MH; Tsao CJ; Su WC; Hwang WS; Chang YF; Chang SY; Yang MH
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1477-84. PubMed ID: 21484308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
    Guigay J; Fayette J; Dillies AF; Sire C; Kerger JN; Tennevet I; Machiels JP; Zanetta S; Pointreau Y; Bozec Le Moal L; Henry S; Schilf A; Bourhis J
    Ann Oncol; 2015 Sep; 26(9):1941-1947. PubMed ID: 26109631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified biweekly cisplatin, docetaxel plus cetuximab (TPEx) as first-line treatment for patients with recurrent/metastatic head and neck cancer.
    Fuchs H; Pammer J; Minichsdorfer C; Posch D; Kornek G; Aretin MB; Fuereder T
    Med Oncol; 2018 Feb; 35(3):32. PubMed ID: 29411154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
    Specht L; Larsen SK; Hansen HS
    Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
    Limaye S; Riley S; Zhao S; O'Neill A; Posner M; Adkins D; Jaffa Z; Clark J; Haddad R
    Oral Oncol; 2013 Aug; 49(8):835-41. PubMed ID: 23727257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
    Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
    Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
    Caponigro F; Massa E; Manzione L; Rosati G; Biglietto M; De Lucia L; Sguotti C; Sganga P; Avallone A; Comella P; Mantovani G; Comella G
    Ann Oncol; 2001 Feb; 12(2):199-202. PubMed ID: 11300324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.